NASDAQ$NXTC
NextCure Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
NextCure reported third quarter 2023 financial results and provided a business update.
NextCure reported a net loss of $14.3 million for the third quarter of 2023, compared to a net loss of $18.9 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $118.2 million as of September 30, 2023, which is expected to fund operations into mid-2025.
- Phase 1b updates for NC410 and NC762 are expected by year end.
- Operational update for NC525 Phase 1a is expected by year end.
- LNCB74 (B7-H4 ADC) was selected as the first antibody drug conjugate candidate from the collaboration with LegoChem Biosciences, Inc.
- Cash of approximately $118 million is expected to fund operations into mid-2025.
Headline financials
Revenue & EPS history
NextCure · Revenue · Quarterly
$0
Forward guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.7%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-1.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+34.8%
Q4 2023
Best reaction
-19.8%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.9% | +6.6% | -16.0% | |
| Q3 2025 | -8.8% | -5.4% | +25.6% | |
| Q2 2025 | -4.4% | +1.9% | -4.8% | |
| Q2 2024 | -1.2% | +1.9% | -4.8% | |
| Q1 2025 | -7.7% | -20.8% | +2.5% | |
| Q4 2024 | +6.1% | -1.7% | -37.7% | |
| Q3 2024 | -1.5% | +18.0% | -12.6% | |
| Q1 2024 | +11.7% | +15.3% | +12.4% | |
| Q4 2023 | +34.8% | +39.7% | +13.5% | |
| Q3 2023 | +10.3% | +6.5% | +12.1% | |
| Q2 2023 | -2.9% | -2.3% | -18.9% | |
| Q1 2023 | +4.6% | +14.5% | +14.5% | |
| Q4 2022 | -4.5% | -5.1% | -5.7% | |
| Q3 2022 | -19.8% | -31.2% | -42.9% | |
| Q2 2022 | +9.8% | +14.0% | -5.1% | |
| Q1 2022 | -4.5% | -15.1% | +4.8% | |
| Q4 2021 | -1.4% | +0.4% | +2.7% | |
| Q3 2021 | -1.4% | -23.5% | -34.5% | |
| Q2 2021 | +5.8% | +3.2% | +7.5% | |
| Q1 2021 | +3.4% | +5.0% | -1.0% | |
| Q4 2020 | -2.0% | +2.1% | -12.7% | |
| Q3 2020 | -4.3% | +0.9% | +11.0% | |
| Q2 2020 | -1.3% | -3.1% | -14.2% | |
| Q1 2020 | +12.2% | +4.0% | -24.8% | |
| Q4 2019 | -12.3% | +4.0% | +5.2% | |
| Q3 2019 | -3.3% | -7.6% | +31.3% | |
| Q2 2019 | +11.7% | +11.1% | +53.9% | |
| Q1 2019 | -6.8% | -6.3% | +0.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro